4D MOLECULAR THERAPEUTICS, INC. - Annual Financials - Equity (SEC)

Updated on January 3, 2026.

Income Statement

Related Topics: SEC Topic List.

Data Source: SEC.

See details in table below.

You can see similar for other companies.

4D MOLECULAR THERAPEUTICS, INC. - Annual Equity (In Thousands of USD, Except Per Share Amounts)

Breakdown	2024-12-31	2023-12-31	2022-12-31
Stockholders' Equity, beginning balances	229	4	547020
Stockholders' Equity, beginning balances (in shares)	45793.942	43075.218	32626.627
Issuance of common stock upon exercise of stock options and warrants		7310
Issuance of common stock upon exercise of stock options and warrants (in shares)		574.74
Issuance of common stock upon exercise of stock options and vesting of RSUs	4580
Issuance of common stock upon exercise of stock options and vesting of RSUs (in shares)	427.036
Issuance of common stock for the offering program, net of issuance costs	15263	1
Issuance of common stock for the offering program, net of issuance costs (in shares)	585.938	1098.612
ATM offering costs		680
Issuance of pre-funded warrant for common stock conversions (in shares)	-6310
Stock-based compensation expense	26116	19665
Issuance of common stock - 2020 ESPP	1258	1178
Issuance of common stock - 2020 ESPP (in shares)	170.436	150.239
Vesting of common stock warrants issued for services	66	88
Net unrealized gain on marketable securities	213	1212
Net loss	-160868	-100837
Stockholders' Equity, ending balances	229	4	547020
Stockholders' Equity, ending balances (in shares)	45793.942	43075.218	32626.627